ketorolac has been researched along with Headache in 19 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
Headache: The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intranasal ketamine and intravenous ketorolac both effectively reduced headaches." | 9.51 | Comparison of the efficacy of intranasal ketamine versus intravenous ketorolac on acute non-traumatic headaches: a randomized double-blind clinical trial. ( Baigrezaii, H; Meysami, A; Nazarianpirdosti, M; Safari-Faramani, R; Sarvari, HR, 2022) |
| "Post-treatment with ketorolac was more effective in attenuating PACAP38-induced headache compared to sumatriptan." | 9.34 | Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache. ( Al-Karagholi, MA; Amin, FM; Arngrim, N; Ashina, M; Ghanizada, H; Larsson, HBW; Metcalf-Clausen, M; Mørch-Rasmussen, M, 2020) |
| "We compare metoclopramide 20 mg intravenously, combined with diphenhydramine 25 mg intravenously, with ketorolac 30 mg intravenously in adults with tension-type headache and all nonmigraine, noncluster recurrent headaches." | 9.17 | A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches. ( Adewunmi, V; Bijur, PE; Campbell, C; Esses, D; Friedman, BW; Gallagher, EJ; Solorzano, C, 2013) |
| "In a prospective, double-blind, randomized study, ketorolac 60 mg, meperidine 50 mg plus promethazine 25 mg, and normal saline given by intramuscular injection were compared as treatment for acute headache crises." | 9.08 | The placebo effect in acute headache management: ketorolac, meperidine, and saline in the emergency department. ( Carter, T; Gracely, RH; Harden, RN; Warner, G, 1996) |
| "Headache is one of the most common neurological conditions among emergency department visits (ED), although the best therapy has not been identified yet." | 7.01 | Randomised trial of IV metoclopramide vs IV ketorolac in treatment of acute primary headaches. ( Eslami, K; Kouti, L; Majdinasab, N; Motamed, H; Soltani, KM, 2021) |
| "Intranasal ketamine and intravenous ketorolac both effectively reduced headaches." | 5.51 | Comparison of the efficacy of intranasal ketamine versus intravenous ketorolac on acute non-traumatic headaches: a randomized double-blind clinical trial. ( Baigrezaii, H; Meysami, A; Nazarianpirdosti, M; Safari-Faramani, R; Sarvari, HR, 2022) |
| "The objective of this study was to assess the efficacy and safety of a common monotherapy (intravenous [iv] metoclopramide) compared to a combination strategy (adding iv ketorolac to metoclopramide) in children presenting for acute treatment of migraine headache in the emergency department (ED)." | 5.51 | A randomized trial of ketorolac and metoclopramide for migraine in the emergency department. ( Ali, S; Johnson, DW; Newton, AS; Richer, LP; Rosychuk, RJ; Rowe, BH, 2022) |
| " Compared to other active drugs, it only showed a lower significant effect compared with granisetron regarding headache change while it showed significantly higher effects only with placebo in both rescue medication needs and headache-free symptoms and valproate in only rescue medication need." | 5.41 | The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials. ( Abd-ElGawad, M; Abdelhay, HM; Abdelmonem, H; Abdelwadoud, GT; Ahmed, AE; Al-Dardery, NM; Alhosini, ANM; Kamel, MA; Mohamed, SW, 2023) |
| "Post-ECT headache is typically treated with acetaminophen or nonsteroidal anti-inflammatory drugs but occasionally requires agents such as sumatriptan, opioids, or β-blockers." | 5.38 | Treatment of post-electroconvulsive therapy headache with topical methyl salicylate. ( Logan, CJ; Stewart, JT, 2012) |
| "Post-treatment with ketorolac was more effective in attenuating PACAP38-induced headache compared to sumatriptan." | 5.34 | Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache. ( Al-Karagholi, MA; Amin, FM; Arngrim, N; Ashina, M; Ghanizada, H; Larsson, HBW; Metcalf-Clausen, M; Mørch-Rasmussen, M, 2020) |
| "We compare metoclopramide 20 mg intravenously, combined with diphenhydramine 25 mg intravenously, with ketorolac 30 mg intravenously in adults with tension-type headache and all nonmigraine, noncluster recurrent headaches." | 5.17 | A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches. ( Adewunmi, V; Bijur, PE; Campbell, C; Esses, D; Friedman, BW; Gallagher, EJ; Solorzano, C, 2013) |
| "In a prospective, double-blind, randomized study, ketorolac 60 mg, meperidine 50 mg plus promethazine 25 mg, and normal saline given by intramuscular injection were compared as treatment for acute headache crises." | 5.08 | The placebo effect in acute headache management: ketorolac, meperidine, and saline in the emergency department. ( Carter, T; Gracely, RH; Harden, RN; Warner, G, 1996) |
| " Commonly used pharmacotherapies for primary headaches were intravenous dopamine receptor antagonists (69%), co-administration of ketorolac and a dopamine receptor antagonist (54." | 4.12 | Current practice for primary headache disorders and perspectives on peripheral nerve blocks among emergency physicians in Canada: A national survey. ( James, D; Patel, D; Perry, JJ; Taljaard, M; Yadav, K, 2022) |
| "Headache is one of the most common neurological conditions among emergency department visits (ED), although the best therapy has not been identified yet." | 3.01 | Randomised trial of IV metoclopramide vs IV ketorolac in treatment of acute primary headaches. ( Eslami, K; Kouti, L; Majdinasab, N; Motamed, H; Soltani, KM, 2021) |
| " Efficacy assessments included pain intensity, which was measured on a 0- to 100-mm visual analog scale, total pain relief, and global pain evaluation up to 8 hours after dosing or until patients required rescue analgesia." | 2.75 | Intranasal ketorolac for pain secondary to third molar impaction surgery: a randomized, double-blind, placebo-controlled trial. ( Grant, GM; Mehlisch, DR, 2010) |
| "Post-ECT headache is typically treated with acetaminophen or nonsteroidal anti-inflammatory drugs but occasionally requires agents such as sumatriptan, opioids, or β-blockers." | 1.38 | Treatment of post-electroconvulsive therapy headache with topical methyl salicylate. ( Logan, CJ; Stewart, JT, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 10 (52.63) | 2.80 |
| Authors | Studies |
|---|---|
| Soltani, KM | 1 |
| Motamed, H | 1 |
| Eslami, K | 1 |
| Majdinasab, N | 1 |
| Kouti, L | 1 |
| Chowdhury, SS | 1 |
| Shaw, M | 1 |
| Berezowski, I | 1 |
| Abdelmonem, A | 1 |
| Patel, J | 1 |
| Sarvari, HR | 1 |
| Baigrezaii, H | 1 |
| Nazarianpirdosti, M | 1 |
| Meysami, A | 1 |
| Safari-Faramani, R | 1 |
| Atif, H | 1 |
| McGhee, J | 1 |
| Patel, D | 1 |
| Taljaard, M | 1 |
| Yadav, K | 1 |
| James, D | 1 |
| Perry, JJ | 2 |
| Richer, LP | 1 |
| Ali, S | 1 |
| Johnson, DW | 1 |
| Rosychuk, RJ | 1 |
| Newton, AS | 1 |
| Rowe, BH | 2 |
| Abdelmonem, H | 1 |
| Abdelhay, HM | 1 |
| Abdelwadoud, GT | 1 |
| Alhosini, ANM | 1 |
| Ahmed, AE | 1 |
| Mohamed, SW | 1 |
| Al-Dardery, NM | 1 |
| Abd-ElGawad, M | 1 |
| Kamel, MA | 1 |
| Ghanizada, H | 1 |
| Al-Karagholi, MA | 1 |
| Arngrim, N | 1 |
| Mørch-Rasmussen, M | 1 |
| Metcalf-Clausen, M | 1 |
| Larsson, HBW | 1 |
| Amin, FM | 1 |
| Ashina, M | 1 |
| Wells, S | 1 |
| Stiell, IG | 1 |
| Vishnyakova, E | 1 |
| Lun, R | 1 |
| Nemnom, MJ | 1 |
| Saeedi, M | 1 |
| Shahvaran, SM | 1 |
| Ramezani, M | 1 |
| Rafiemanesh, H | 1 |
| Karimialavijeh, E | 1 |
| Villa-Roel, C | 1 |
| Krebs, LD | 1 |
| Friedman, BW | 1 |
| Adewunmi, V | 1 |
| Campbell, C | 1 |
| Solorzano, C | 1 |
| Esses, D | 1 |
| Bijur, PE | 1 |
| Gallagher, EJ | 1 |
| De Cesaris, F | 1 |
| Fanciullacci, M | 1 |
| Pietrini, U | 1 |
| Anselmi, B | 1 |
| Del Bene, E | 1 |
| Grant, GM | 1 |
| Mehlisch, DR | 1 |
| Logan, CJ | 1 |
| Stewart, JT | 1 |
| Rossi, P | 1 |
| Nappi, G | 1 |
| Harden, RN | 1 |
| Gracely, RH | 1 |
| Carter, T | 1 |
| Warner, G | 1 |
| McConnell, EA | 1 |
| Morgenstern, LB | 1 |
| Huber, JC | 1 |
| Luna-Gonzales, H | 1 |
| Saldin, KR | 1 |
| Grotta, JC | 1 |
| Shaw, SG | 1 |
| Knudson, L | 1 |
| Frankowski, RF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Role of Inflammation and Vasodilatation in PACAP38-induced Headache Using MRI on Healthy Subjects[NCT03585894] | 34 participants (Actual) | Interventional | 2018-08-01 | Completed | |||
| An RCT of Metoclopramide/Diphenhydramine vs. Ketorolac Alone for Tension-type Headache[NCT01011673] | Phase 4 | 123 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| The Check Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine. A Multi-Center, Randomized Double-Blind, Clinical Control Trial.[NCT02657031] | Phase 4 | 54 participants (Actual) | Interventional | 2016-03-17 | Completed | ||
| A Randomized Double-blind Comparative Efficacy Trial of IV Acetaminophen Versus IV Ketorolac for Emergency Department Treatment of Generalized Headache[NCT03472872] | Phase 4 | 500 participants (Actual) | Interventional | 2017-09-05 | Terminated (stopped due to no longer recruiting or studying) | ||
| Intravenous Fluids in Benign Headaches Trail: A Randomized Single Blind Clinical Trial[NCT03185130] | Phase 4 | 58 participants (Actual) | Interventional | 2017-05-16 | Completed | ||
| Evaluating Post-operative Pain Management Efficacy of Intra Nasal Ketorolac in Ambulatory Urological Surgeries-A Randomized Double-blinded Placebo Controlled Study[NCT01736358] | Phase 4 | 50 participants (Actual) | Interventional | 2012-10-31 | Terminated (stopped due to Interim analysis showed futility of primary endpoint) | ||
| Improving the Headache Management Care in the Emergency Unit by Using a Biological Marker: S100B Protein.[NCT03490500] | 63 participants (Actual) | Observational | 2018-10-24 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
At baseline at at 60 minutes, all patients were asked to describe their pain on a scale from 0 to 10, with 0 representing no pain and 10 the worst imaginable. The primary outcome is the 60 minute score subtracted from the baseline score (NCT01011673)
Timeframe: Baseline, 60 minutes
| Intervention | units on a scale (Mean) |
|---|---|
| Ketorolac | 3.8 |
| Metoclopramide | 5.1 |
"24 hours after the emergency department visit, patients were asked, The next time you come to the Er with this type of headache, do you want to receive the same medication? Affirmative answers are tabulated here." (NCT01011673)
Timeframe: 24 hours
| Intervention | participants (Number) |
|---|---|
| Ketorolac | 45 |
| Metoclopramide | 53 |
Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum anxiety. A change of 0 mm corresponds to no change in anxiety level, and a negative value indicates worsening of the anxiety after the medication. (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | mm (Mean) |
|---|---|
| Control Arm | 33.7 |
| Study Arm | 21.2 |
Reduction in 100 mm Visual Analog Scale (VAS) Score. Positive values represent a reduction in headache severity. The maximum possible change in VAS score is 100 mm, representing the complete relief of a maximally severe headache. A change of 0 mm corresponds to no change in headache severity, and a negative value indicates worsening of the headache after the medication. (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | mm (Mean) |
|---|---|
| Control Arm | 63.5 |
| Study Arm | 43.5 |
Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum nausea. A change of 0 mm corresponds to no change in nausea level, and a negative value indicates worsening of the nausea after the medication. (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | mm (Mean) |
|---|---|
| Control Arm | 38.9 |
| Study Arm | 22.9 |
Yes/No (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | participants (Number) |
|---|---|
| Control Arm | 2 |
| Study Arm | 3 |
Yes/No (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | participants (Number) |
|---|---|
| Control Arm | 3 |
| Study Arm | 3 |
To find the incidence of immediate (until discharge) and 24hrs post operative side effects in the target population. (NCT01736358)
Timeframe: 24 hours after procedure
| Intervention | number of events (Number) |
|---|---|
| Intranasal Ketoralac | 0 |
| Placebo | 0 |
To evaluate the post operative pain score using the Visual Analog Scale (VAS) 2 hours after surgery. The scale for VAS is 0 is no pain to 10 being the worst pain. (NCT01736358)
Timeframe: 2 hours after surgery
| Intervention | score on a scale (Median) |
|---|---|
| Intranasal Ketoralac | 4 |
| Placebo | 3 |
To evaluate the post operative pain score using the Visual Analog Scale (VAS) 1 hour after surgery. The scale for VAS is 0 is no pain to 10 being the worst pain. (NCT01736358)
Timeframe: 1 hour after surgery
| Intervention | score on a scale (Median) |
|---|---|
| Intranasal Ketoralac | 3.5 |
| Placebo | 4.5 |
To evaluate the post operative pain score using the Visual Analog Scale (VAS) 30 minutes after surgery. The scale for VAS is 0 is no pain to 10 being the worst pain. (NCT01736358)
Timeframe: 30 minutes after surgery
| Intervention | score on a scale (Median) |
|---|---|
| Intranasal Ketoralac | 4 |
| Placebo | 3.5 |
this study will assess the effect of perioperative usage of single-dose of intranasal ketorolac on post operative opioid requirements within 3 hours after surgery. (NCT01736358)
Timeframe: 3 hours after surgery
| Intervention | mg (Median) |
|---|---|
| Intranasal Ketoralac | 27.43 |
| Placebo | 30 |
1 review available for ketorolac and Headache
| Article | Year |
|---|---|
The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials.
Topics: Chlorpromazine; Granisetron; Headache; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Nausea | 2023 |
9 trials available for ketorolac and Headache
| Article | Year |
|---|---|
Randomised trial of IV metoclopramide vs IV ketorolac in treatment of acute primary headaches.
Topics: Administration, Intravenous; Adult; Anti-Inflammatory Agents, Non-Steroidal; Dopamine D2 Receptor An | 2021 |
IV metoclopramide Vs IV ketorolac in the treatment of acute primary headaches: A randomized clinical trial.
Topics: Acute Pain; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Headache; Humans; Ketorola | 2022 |
Comparison of the efficacy of intranasal ketamine versus intravenous ketorolac on acute non-traumatic headaches: a randomized double-blind clinical trial.
Topics: Administration, Intranasal; Analgesics; Double-Blind Method; Headache; Humans; Ketamine; Ketorolac | 2022 |
A randomized trial of ketorolac and metoclopramide for migraine in the emergency department.
Topics: Adolescent; Child; Double-Blind Method; Emergency Service, Hospital; Headache; Humans; Ketorolac; Me | 2022 |
Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Double-Blind Method; Female; Hea | 2020 |
Comparing the effects of 3 oxygen delivery methods plus intravenous ketorolac on primary headaches: A randomized clinical trial.
Topics: Administration, Intravenous; Adult; Anti-Inflammatory Agents, Non-Steroidal; Emergency Service, Hosp | 2020 |
A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diphenhydramine; Dopamine Antagonists; Double-Blind | 2013 |
A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diphenhydramine; Dopamine Antagonists; Double-Blind | 2013 |
A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diphenhydramine; Dopamine Antagonists; Double-Blind | 2013 |
A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diphenhydramine; Dopamine Antagonists; Double-Blind | 2013 |
A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diphenhydramine; Dopamine Antagonists; Double-Blind | 2013 |
A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diphenhydramine; Dopamine Antagonists; Double-Blind | 2013 |
A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diphenhydramine; Dopamine Antagonists; Double-Blind | 2013 |
A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diphenhydramine; Dopamine Antagonists; Double-Blind | 2013 |
A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diphenhydramine; Dopamine Antagonists; Double-Blind | 2013 |
A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diphenhydramine; Dopamine Antagonists; Double-Blind | 2013 |
A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diphenhydramine; Dopamine Antagonists; Double-Blind | 2013 |
A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diphenhydramine; Dopamine Antagonists; Double-Blind | 2013 |
A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diphenhydramine; Dopamine Antagonists; Double-Blind | 2013 |
A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diphenhydramine; Dopamine Antagonists; Double-Blind | 2013 |
A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diphenhydramine; Dopamine Antagonists; Double-Blind | 2013 |
A randomized trial of intravenous ketorolac versus intravenous metoclopramide plus diphenhydramine for tension-type and all nonmigraine, noncluster recurrent headaches.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Diphenhydramine; Dopamine Antagonists; Double-Blind | 2013 |
Intranasal ketorolac for pain secondary to third molar impaction surgery: a randomized, double-blind, placebo-controlled trial.
Topics: Administration, Intranasal; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhi | 2010 |
The placebo effect in acute headache management: ketorolac, meperidine, and saline in the emergency department.
Topics: Acute Disease; Adult; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-St | 1996 |
9 other studies available for ketorolac and Headache
| Article | Year |
|---|---|
Randomized IV metoclopramide vs IV ketorolac in treatment of acute primary headache.
Topics: Acute Pain; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Headache; Humans; Ketorola | 2022 |
Current practice for primary headache disorders and perspectives on peripheral nerve blocks among emergency physicians in Canada: A national survey.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Canada; Dopamine Antagonists; Emergency Service, Hospital; | 2022 |
Optimal management strategies for primary headache in the emergency department.
Topics: Adult; Emergency Service, Hospital; Female; Headache; Humans; Ketorolac; Metoclopramide; Migraine Di | 2021 |
How to diagnose and treat benign headaches.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dexamethasone; Dopamine D2 Receptor Antagonists; Drug Thera | 2019 |
Defining neuralgiform headache with ipsilateral autonomic symptoms: case report in a headache center.
Topics: Aged; Amines; Analgesics, Opioid; Anticonvulsants; Autonomic Nervous System; Cyclohexanecarboxylic A | 2008 |
Treatment of post-electroconvulsive therapy headache with topical methyl salicylate.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Depressive Disorder, Major; | 2012 |
Bath-related headache: the first European case.
Topics: Adrenergic beta-Antagonists; Analgesics; Baths; Female; Headache; Humans; Hypertension; Ketorolac; M | 2006 |
When your postoperative patient has a setback.
Topics: Adult; Analgesics, Non-Narcotic; Dizziness; Female; Headache; Humans; Ketorolac; Nursing Assessment; | 1996 |
Headache in the emergency department.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Diagnosis, Differential; Drug T | 2001 |